Skip to main content

Richard Edelson, MD

Richard Edelson, MD

Aaron B. and Marguerite Lerner Professor of Dermatology

Chair and Professor

Department of Dermatology

Yale School of Medicine

Related Videos

As a pioneer in the field of extracorporeal photopheresis (ECP) can you provide some background and history on how this therapeutic strategy was developed and for what challenging conditions, in particular, in CTCL?

As a pioneer in the field of extracorporeal photopheresis (ECP) can you provide some background and history on how this therapeutic strategy was developed and for what challenging conditions, in particular, in CTCL?

Can you discuss what is unique about ECP and why this therapy provides an acceptable balance of efficacy and safety for malignant conditions as well as related conditions?

Can you discuss what is unique about ECP and why this therapy provides an acceptable balance of efficacy and safety for malignant conditions as well as related conditions?

Can you explain the importance of the fact that ECP provides dual or bifurcated effects on immune modulation, i.e., it can potentiate immune response against malignancies such as CTCL, and tolerize immune response in such conditions as GVHD?

Can you explain the importance of the fact that ECP provides dual or bifurcated effects on immune modulation, i.e., it can potentiate immune response against malignancies such as CTCL, and tolerize immune response in such conditions as GVHD?

Can you summarize the mechanistic underpinnings of ECP and its role in anti-cancer therapy and future applications?

Can you summarize the mechanistic underpinnings of ECP and its role in anti-cancer therapy and future applications?

Can you be specific about how you interpret the results of the CD4/CD8 T-cell ratios in order to determine suitability for ECP therapy? And what is the role of anti-T-cell antibodies for patient screening?

Can you be specific about how you interpret the results of the CD4/CD8 T-cell ratios in order to determine suitability for ECP therapy? And what is the role of anti-T-cell antibodies for patient screening?

Once you and colleagues in the field had determined that dendritic presenting cells (DPCs) were critical mediators of the therapeutic effects of ECP, how did you determine the actual mechanism by which ECP activated DPCs?

Once you and colleagues in the field had determined that dendritic presenting cells (DPCs) were critical mediators of the therapeutic effects of ECP, how did you determine the actual mechanism by which ECP activated DPCs?

Can you discuss the findings, implications, consensus agreements, and recommendations issued by the American Council of Extracorporeal Photopheresis (ACE), which was commissioned by ASFA?

Can you discuss the findings, implications, consensus agreements, and recommendations issued by the American Council of Extracorporeal Photopheresis (ACE), which was commissioned by ASFA?

How enduring is the response to ECP in appropriately selected patients with CTCL? What percentage of CTCL patients who have failed initial therapy can be expected to respond? And what are the characteristics of the dose-response curve?

How enduring is the response to ECP in appropriately selected patients with CTCL? What percentage of CTCL patients who have failed initial therapy can be expected to respond? And what are the characteristics of the dose-response curve?

What explains the bi-directional immunomodulatory and therapeutic effects of ECP, and what are the practical implications of its deployment against a broad spectrum of disease states?

What explains the bi-directional immunomodulatory and therapeutic effects of ECP, and what are the practical implications of its deployment against a broad spectrum of disease states?